The University of Basel, Switzerland, and Micromet AG have published a new study on the frequent high-level expression of antibody target epithelial cell adhesion molecule (Ep-CAM) in colon, lung, prostate and gastric cancers. The report has been published in the British Journal of Cancer (2006, 94: 128 – 135) (1). Ep-CAM is the target for Micromet’s human antibody adecatumumab (MT201), which currently is in two phase II clinical trials in prostate and metastatic breast cancer, and is partnered with Serono.
